DyslipidemiasHyperlipidemiasHypolipidemic AgentsTriglyceridesCholesterol, LDLCholesterol, HDLMetabolic Syndrome XLipidsRisk FactorsFenofibrateCardiovascular DiseasesObesityCholesterolInsulin ResistanceHydroxymethylglutaryl-CoA Reductase InhibitorsNiacinDiabetes Mellitus, Type 2HypertriglyceridemiaAtherosclerosisLipid MetabolismHypertensionFluorobenzenesAnticholesteremic AgentsPrevalenceAzetidinesBlood GlucoseDiabetes MellitusFibric AcidsMetabolic DiseasesBody Mass IndexFatty LiverCross-Sectional StudiesLipodystrophyHypercholesterolemiaLipoproteinsObesity, AbdominalHeptanoic AcidsApolipoproteins BSimvastatinClofibric AcidInsulinLiverHyperlipidemia, Familial CombinedApolipoprotein C-IIIBiological MarkersDiabetes ComplicationsLipid Metabolism DisordersPPAR alphaFructoseGlucose Metabolism DisordersPyrrolesLuxembourgHyperglycemiaCholesterol, VLDLWaist CircumferenceLife StyleJapanRisk AssessmentApolipoproteins EAnti-Obesity AgentsChinaAnthropometryDrug Therapy, CombinationHyperinsulinismHypoglycemic AgentsAdipose TissuePractice Guidelines as TopicSex FactorsCoronary Artery DiseaseAdiponectinAsian Continental Ancestry GroupHIV-Associated Lipodystrophy SyndromeTreatment OutcomeBlood PressureGlucose Tolerance TestAge FactorsIntra-Abdominal FatDietary FatsDiabetic AngiopathiesLipoproteins, VLDLBrazilCohort StudiesKidney Failure, ChronicGemfibrozilPeroxisome Proliferator-Activated ReceptorsLogistic ModelsReceptors, LDLDiet, High-FatRisk Reduction BehaviorGlucose IntoleranceAntiretroviral Therapy, Highly ActiveLipoprotein LipaseCoronary DiseaseLipoproteins, LDLComorbidityC-Reactive ProteinCase-Control StudiesRetrospective StudiesWaist-Hip RatioTrigonella